XARELTO®: Efficacy profile for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients◇
VTE RISK REDUCTION IN THE MAGELLAN SUBGROUP
EFFICACY RESULTS AT DAY 10 AND DAY 35 IN ACUTELY ILL MEDICAL PATIENTS VERSUS STANDARD OF CARE IN THE MAGELLAN SUBGROUP◇*
At Day 10 and Day 35, XARELTO® demonstrated lower rates of VTE when compared with enoxaparin/placebo
- Day 10: 2.4% (58/2385) of patients taking XARELTO® experienced a VTE event versus 3.0% (72/2433) of patients taking enoxaparin
- Day 35: 3.9% (94/2419) of patients taking XARELTO® experienced a VTE event versus 5.7% (143/2506) of patients taking enoxaparin/placebo
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
*Patients excluded due to high risk of bleeding: history of bronchiectasis, pulmonary cavitation, or pulmonary hemorrhage; active cancer (ie, undergoing acute, in-hospital cancer treatment); active gastroduodenal ulcer in the 3 months prior to treatment; history of bleeding within the last 3 months prior to treatment; or receiving DAPT.
†Primary efficacy outcomes: the composite of asymptomatic proximal DVT, symptomatic proximal or distal DVT, symptomatic nonfatal PE, or VTE-related death.
‡Patients received either XARELTO® or placebo once daily for 35 days ±4 days starting in hospital and continuing post hospital discharge, or received enoxaparin or placebo once daily for 10 days ±4 days in the hospital.
§The decision regarding initiation setting should be based on the prescriber's clinical judgment.
BMI = body mass index; DAPT = dual antiplatelet therapy; DVT = deep vein thrombosis; mITT = modified intent-to-treat; PE = pulmonary embolism; RR = relative risk; VTE = venous thromboembolism.